The PSMAcTION trial is a Phase II/III open-label, multicenter study evaluating the investigational drug AAA817 (225Ac-PSMA-617) for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Patients who previously received androgen receptor pathway inhibitors (ARPI), taxane-based chemotherapy, and progressed after [177Lu]Lu-PSMA therapy are eligible.
The Phase II portion gathers data to support dosing, while the Phase III component compares AAA817’s efficacy and safety against standard-of-care treatments.
Participants will be randomly assigned to either the AAA817 arm or investigator-chosen standard treatments.
This study aims to offer a new therapeutic option for advanced mCRPC, providing hope for patients with limited treatment alternatives.
Why I Choose an Unproven Treatment
Update on Prostate Cancer Vaccines from Previous Posts done over the last few years... and a new one...